Publications by authors named "G S Korbutt"
Type 1 diabetes mellitus (T1DM) is a growing global health concern that affects approximately 8.5 million individuals worldwide. T1DM is characterized by an autoimmune destruction of pancreatic β cells, leading to a disruption in glucose homeostasis.
View Article and Find Full Text PDFArticle Synopsis
- Beta cell replacement therapies in the subcutaneous space offer benefits like easier access, noninvasive monitoring, and simpler graft removal compared to other locations.
- Research on prevascularized subcutaneous sites showed that the pre-formed blood vessel barriers help retain injected poly(ethylene oxide)s (PEOs) more effectively than unmodified sites.
- Findings reveal that larger molecules (greater than 35 kDa) struggle to enter circulation from these sites, emphasizing the importance of molecular size for improving the survival of beta cell grafts.
One strategy to prevent islet rejection is to create a favorable immune-protective local environment at the transplant site. Herein, we utilize localized cyclosporine A (CsA) delivery to islet grafts via poly(lactic-co-glycolic acid) (PLGA) microparticles to attenuate allograft rejection. CsA-eluting PLGA microparticles were prepared using a single emulsion (oil-in-water) solvent evaporation technique.
View Article and Find Full Text PDFArticle Synopsis
- Beta cell replacement therapies show promise for improving blood sugar control in type 1 diabetes, but long-term immune suppression limits their effectiveness compared to insulin.
- Researchers studied a coating made from poly(N-vinylpyrrolidone) and tannic acid (PVPON/TA) to protect transplanted islets from the immune system while maintaining their function.
- Results indicated that both coated and non-coated islets performed similarly in lab tests, and the PVPON/TA-coating improved transplant outcomes by reducing inflammation and delaying rejection in mice.
Unlabelled: Intrahepatic islet transplantation for type 1 diabetes is limited by the need for multiple infusions and poor islet viability posttransplantation. The development of alternative transplantation sites is necessary to improve islet survival and facilitate monitoring and retrieval. We tested a clinically proven biodegradable temporizing matrix (BTM), a polyurethane-based scaffold, to generate a well-vascularized intracutaneous "neodermis" within the skin for islet transplantation.
View Article and Find Full Text PDF